Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study
EV exhibited favorable organ-specific tumor responses in mUC, with particularly high efficacy against liver metastasis. However, response rates were lower in bone metastases. No significant differences in organ-specific overall survival were observed.
Authors
- Mimu Ishikawa
- Takaya Sasaki (ORCID: https://orcid.org/0000-0001-9525-2638)
- Fumihiko Urabe (ORCID: https://orcid.org/0000-0002-2599-8183)
- Kosuke Iwatani (ORCID: https://orcid.org/0000-0001-5428-852X)
- Naoki Uchida (ORCID: https://orcid.org/0000-0002-4220-9625)
- Yuhei Koike (ORCID: https://orcid.org/0000-0003-0254-686X)
- Kojiro Tashiro
- Sotaro Kayano (ORCID: https://orcid.org/0009-0001-0895-1551)
- Y Taneda
- Shuhei Hara (ORCID: https://orcid.org/0009-0001-9842-3612)
- Takashi Ohtsuka (ORCID: https://orcid.org/0000-0002-8039-9159)
- Yu Imai (ORCID: https://orcid.org/0000-0003-0971-4205)
- Koichi Aikawa (ORCID: https://orcid.org/0000-0003-0381-3368)
- Minoru Nakazono
- Mahito Atsuta
- Takahiro Kimura
- Hirokazu Kagawa
- Katsuki Muramoto
- Yuma Goto
- Jun Miki
Institutions
- Jikei University School of Medicine (JP)
- Katsushika Medical Center (JP)
- Kameda Medical Center (JP)
- Tokyo Metropolitan Tama-Hokubu Medical Center (JP)
- Tokyo Metropolitan Hiroo Hospital (JP)
- Fujieda Municipal General Hospital (JP)
- Jikei University Kashiwa hospital (JP)
- Fuji Heavy Industries Health Insurance Society Ota Memorial Hospital (JP)
- Nerima General Hospital (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1093/jjco/hyaf060
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.02